Hemodynamics and risk assessment two years after initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension

- Upfront combination therapy with ambrisentan and tadalafil has been reported to improve pulmonary arterial hypertension (PAH) patients more than with either drug alone. However, little is known about long-term associated changes in hemodynamics and risk assessment scores.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research